- Credit Type: CME
- Credit Amount: 2.75
- Cost: Free
- Release: Nov 14, 2014
- Expires: Sep 12, 2017
- Estimated Time to Complete:
2 Hour(s) , 45 Minutes
- System Requirements:
Average User Rating:
Department of Ophthalmology and Visual Sciences
University of Wisconsin
Professor, Department of Biochemistry
Case Western Reserve University
Needs StatementThere has been a recent shift in the treatment of diabetic macular edema (DME) from laser based procedures to intravitreal injections of anti-VEGF drugs. Research into the pathogenesis of DME is now providing a more detailed picture of critical pathways that result in endothelial cell dysfunction. Here, we delve into the basic science of DME and provide a critical update on clinical trial designs and outcomes.
Target AudiencePhysicians, clinical researchers, optometry students, residents, fellows and any healthcare professional interested in ophthalmology
ObjectivesUpon completion of this activity participants will be able to:
1. Discuss pathogenesis of diabetic retinopathy
2. Discuss updates on treatment outcomes for diabetic macular edema
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Kentucky College of Medicine designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
- Patient care
- Medical knowledge
Faculty DisclosureMichael S. Ip, MD (speaker) has relevant financial relationships with a commercial interest: Allergan - Conusltant/Advisor - Concsultant Fee
Dr. Ip does intend to discuss the off-label use of a product.
Timothy S. Kern, PhD (speaker) has relevant financial relationships with a commercial interest: Novo Nordisk - Conusltant - Honorarium
Dr. Kern does not intend to discuss the off-label use of a product.
No planners or content reviewers have any relevant financial relationships to disclose.
Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.